Cynata is going for the High-Risk market. If it's successful in adults, then the steroid refractory market will be a fraction of what it currently is. That definitely impacts Mesoblast. Mesoblast, on the other hand, have no way of reducing the size of the High-Risk market, as they are only aiming to be a:
- second line therapy in paediatric SR-aGvHD
- Third line therapy in adult SR-aGvHD
Why Orphan Drug Designation for mesoblast is IRRELEVANT to Cynata, page-12
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.005(3.13%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $33.50K | 208.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 121461 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 91663 | 8 |
View Market Depth
| Last trade - 12.18pm 25/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |